APTV — Aptiv PLC

The market is focused on the negative: post-spinoff revenue is much smaller, full-year 2026 revenue guidance was cut by $300M at the midpoint due to China softness and OEM program launch delays, and the stock is pinned near its 52-week low. Q2 2026 adjusted EPS of $1.63 beat the $1.43 consensus, but the guidance cut and continued downward estimate revisions have kept the tape bearish.

Looking at the 12 reported quarters, the old Aptiv was a stable $4.8-5.2B-per-quarter revenue business with operating margins mostly in the 8-11% range, aside from Q3 2025's -$175M operating income and -$355M net income, which looks like one-off/impairment charges rather than a normal quarter. The apparent -36% revenue drop from Q1 2026 ($5.09B) to Q2 2026 ($3.27B) is the April 1, 2026 EDS spin-off, not organic deterioration; continuing-operations revenue actually grew about 2% year-over-year in Q2. The reported GAAP trend is therefore distorted by the spinoff, separation costs, and charges. The real underlying picture is a cyclical trough: modest revenue growth, an 18.7% adjusted EBITDA margin, and management guidance of $5.60-$5.80 in FY2026 adjusted EPS.

On reported GAAP, APTV looks expensive at 43.3x TTM EPS of $1.04, but that EPS is depressed by spinoff-related charges and impairments. On forward numbers it is genuinely cheap: at $45.44, the stock trades at about 8.0x the FY2026 adjusted EPS guidance midpoint of $5.70 and about 7.9x the FY2027 analyst EPS estimate of $5.75. Trailing P/S of 0.51 is distorted by the spinoff; on the guided ~$12.7B revenue base it is roughly 0.76x. Versus its own 5-year average P/E of 50x and P/S of 1.43x, the stock is far below historical norms, though those averages are not fully comparable after the business mix change.

The market is pricing in more bad news: a ~8x forward P/E means investors do not fully trust the ~$5.75 EPS estimate, with real worries about China, OEM launch delays, and auto-cycle risk. If Aptiv merely hits its guided EPS and sustains the 18.7% adjusted EBITDA margin, the stock can re-rate toward 10-12x and trade in the high-$50s to high-$60s. If guidance slips again, the low multiple is deserved and the stock could keep grinding near $45 or below. This is a show-me setup: the price is cheap because the earnings estimate is the main risk, not because the market is ignoring obvious value.

As of 2026-08-27, RSI stood at 31.8, near oversold but not yet a confirmed reversal setup. Price at $45.44 was about 7.2% below the 20-day SMA, 17.8% below the 50-day SMA, and 31.4% below the 200-day SMA - a clear, persistent downtrend. Oversold bounces are possible, but the trend is still down, and a meaningful entry signal would likely require reclaiming at least the 20-day average around $49 and stabilizing above the $45.285 52-week low.

• Automotive demand is uneven across regions: Europe was down 8% in Q2 on luxury OEM weakness, and China remains volatile with intense local competition.
• OEM program launch delays directly reduce Aptiv's revenue timing and near-term content attach.
• Declining interest rates have lowered interest expense to $62M in Q2 and support the balance-sheet repair, but consumer auto financing demand is still sensitive to rates.
• Tariff and trade-policy risk on auto parts and cross-border supply chains remains a swing factor.
• The shift to software-defined vehicles, plus physical AI and robotics, creates an optionality tailwind outside traditional autos.

• Q3 2026 earnings, expected late October/early November 2026 - the first full clean quarter of New Aptiv, with Q3 net sales guidance of $3.12-$3.22B to hold or beat.
• Continued execution on removing stranded EDS spinoff costs and expanding adjusted EBITDA margin above the current 18.7%.
• Non-automotive growth momentum: non-auto revenue rose 12% in Q2, including robotics, drones, and data-center applications, plus the new NVIDIA Jetson Orin Nano 2 physical AI support.
• Capital return: roughly $1.8B remaining under the buyback authorization and further debt paydown already reducing interest costs.

• Further guidance cuts from China softness, European OEM weakness, or delayed vehicle launches.
• The post-spinoff revenue base is much smaller and less diversified, so an auto downturn hits New Aptiv harder.
• Adjusted EPS includes add-backs; GAAP profitability is far lower, so earnings quality needs close monitoring.
• Competitive and technology risk in EV transition, software-defined vehicles, and Chinese local supplier share gains.
• Execution risk on the Versigent separation, stranded costs, and customer transition timing.

At $45.44, APTV is priced at roughly 8x forward EPS and is sitting near its 52-week low, so a lot of negative news is already in the stock. The problem is that negative news has kept arriving, and the spinoff makes reported comparisons unreliable. For a patient investor this is a legitimate cyclical/value watchlist candidate, but not yet a high-conviction buy - I would want one or two clean quarters of New Aptiv execution and stabilizing estimates before treating the cheap multiple as confirmation rather than a value trap.

Calculated by applying a 10x multiple to the FY2027 consensus EPS estimate of $5.75 - a conservative cyclical-auto-parts multiple that is well below the post-spinoff-distorted historical P/E but above the current ~8x forward multiple. This deliberately sits below the $68.9 analyst consensus target to account for China/OEM execution risk, weak trailing FCF, and one-off-adjusted earnings quality.